Rongjuan Pei, et al
new strategies directed at modulation of the cellular gene
expression related to antiviral activities. The modulation of
MAPK-ERK pathway led to a change of effectiveness of the
antiviral action of IFN but did not block the inhibition of HCV
replication by IFN signalling. MAPK-ERK and IFN pathways
may act synergistically to regulate HCV replication.
Controversial reports have been published on this topic.
While some reports claimed an enhanced replication of HCV
by inhibition of MEK-ERK pathway
, others indicated
that the inhibition of this pathway could reduce HCV
. Here we demonstrated that MAPK-ERK pathway
and the downstream cell cycle regulators play a significant role
in the regulation of HCV replication and protein expression in
subgenomic containing cell lines. However, when we applied
the MEK inhibitor, U0126, in the HCVcc infectious system, a
reduction of infectious virus produced in the supernatant was
observed. This may indicate a complex role of the MEK-ERK
pathway in the HCV life cycle.
The authors would like to thank Dr. Ralf Bartenschlager and
Dr. M Niepmann for providing cell lines and other reagents.
The authors would also like to thank Dr. Simon Rayner for
kindly reading and criticizing the manuscript.
1. Aktas H, Cai H, Cooper G M. 1997. Ras links growth factor
signaling to the cell cycle machinery via regulation of cyclin d1
and the cdk inhibitor p27kip1. Mol Cell Biol, 17(7): 3850–3857.
2. Alter M J. 1997. Epidemiology of hepatitis c. Hepatology, 26(S3):
3. Bartenschlager R. 2006. Hepatitis c virus molecular clones: From
cdna to infectious virus particles in cell culture. Current Opinion
in Microbiology, 9(4): 416–422.
4. Binder M, Kochs G, Bartenschlager R, et al. 2007. Hepatitis c
virus escape from the interferon regulatory factor 3 pathway by a
passive and active evasion strategy. Hepatology, 46(5):
5. Broering R, Wu J, Meng Z, et al. 2008. Toll-like receptor-
stimulated non-parenchymal liver cells can regulate hepatitis c
virus replication. J Hepatol, 48(6): 914–922.
6. Brunet A, Danie` Le Roux, Lenorm P, et al. 1999. Nuclear
translocation of p42/p44 mitogen-activated protein kinase is
required for growth factor-induced gene expression and cell cycle
entry. The EMBO Journal, 18(3): 664–674.
7. Chang Y, Lei Y, Wu W, et al. 2007. Effect of hepatitis c virus core
protein on interferon-induced antiviral genes expression and its
mechanisms. Virologica Sinica, 22(5): 274-379.
8. Choo Q L, Kuo G, Weiner a J, et al. 1989. Isolation of a cdna
clone derived from a blood-borne non-a, non-b viral hepatitis
genome. Science, 244(4902): 359–362.
9. Cyert M S. 2001. Regulation of nuclear localization during
signaling. J Biol Chem
, 276(24): 20805–20808.
imia G M, Evangelisti C, Alonzi T, et al. 2004. Conventional
protein kinase c inhibition prevents alpha interferon-mediated
hepatitis c virus replicon clearance by impairing stat activation. J
Virol, 78(23): 12809–12816.
11. Foy E, Li K, Wang C, et al. 2003. Regulation of interferon
regulatory factor-3 by the hepatitis c virus serine protease. Science,
12. Foy E, Li K, Sumpter R, Jr, et al. 2005. Control of antiviral
defenses through hepatitis c virus disruption of retinoic
acid-inducible gene-i signaling. Proc Natl Acad Sci U S A, 102(8):
13. Frese M, Schwarzle V, Barth K, et al. 2002. Interferon-gamma
inhibits replication of subgenomic and genomic hepatitis c virus
rnas. Hepatology, 35(3): 694–703.
14. Gretton S, Hughes M,Harris M. 2010. Hepatitis c virus rna
replication is regulated by ras-erk signalling. J Gen Virol, 91(Pt 3):
15. Guo J-T, Zhu Q, Seeger C. 2003. Cytopathic and noncytopathic
interferon responses in cells expressing hepatitis c virus
subgenomic replicons. J Virol, 77(20): 10769–10779.
16. Huang Y, Chen X C, Konduri M, et al. 2006. Mechanistic link
between the anti-hcv effect of interferon gamma and control of
viral replication by a ras-mapk signaling cascade. Hepatology,
17. Kawada M, Yamagoe S, Murakami Y, et al. 1997. Induction of
p27kip1 degradation and anchorage independence by ras through
the map kinase signaling pathway. Oncogene, 15(6): 629–637.
18. Krieger N, Lohmann V, Bartenschlager R.
of hepatitis c virus rna replication by cell culture-adaptive
mutations. J Virol, 75(10): 4614–4624.
19. Li K, Foy E, Ferreon J C, et al. 2005. Immune evasion by
hepatitis c virus ns3/4a protease-mediated cleavage of the toll-like
receptor 3 adaptor protein trif. Proc Natl Acad Sci U S A, 102(8):
20. Lindenbach B D, Evans M J, Syder a J, et al. 2005. Complete
replication of hepatitis c virus in cell culture. Science, 309(5734):
21. Lohmann V, Ouml, Rner F, et al. 1999. Replication of
subgenomic hepatitis c virus rnas in a hepatoma cell line. Science,
22. Maccorkle R, Tan T-H. 2005. Mitogen-activated protein kinases
in cell-cycle control. Cell Biochemistry and Biophysics, 43(3):
23. Macdonald A, Chan J K Y, Harris M. 2005. Perturbation of
epidermal growth factor receptor complex formation and ras
signalling in cells harbouring the hepatitis c virus subgenomic
replicon. J Gen Virol, 86(4): 1027–1033.
24. Macdonald A, Crowder K, Street A, et al. 2003. The hepatitis c
virus non-structural ns5a protein inhibits activating protein-1
function by perturbing ras-erk pathway signaling. J Biol Chem,
25. Mankouri J, Griffin S, Harris M. 2008. The hepatitis c virus
non-structural protein ns5a alters the trafficking profile of the